4
|
Ferfar Y, Morinet S, Espitia O, Agard C, Vautier M, Comarmond C, Desbois AC, Domont F, Resche-Rigon M, Cacoub P, Biard L, Saadoun D. Spectrum and Outcome of Noninfectious Aortitis. J Rheumatol 2021; 48:1583-1588. [PMID: 34210830 DOI: 10.3899/jrheum.201274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/12/2021] [Indexed: 11/22/2022]
Abstract
OBJECTIVE To assess the spectrum and long-term outcome of patients with noninfectious aortitis. METHODS We performed a retrospective multicenter study of 353 patients (median age at diagnosis was 62 [IQR 46-71] yrs and 242 [68.6%] patients were women) with noninfectious aortitis. Factors associated with vascular complications were assessed in multivariate analysis. RESULTS We included 136 patients with giant cell arteritis (GCA), 96 with Takayasu arteritis (TA), 73 with clinically isolated aortitis (CIA), and 48 with aortitis secondary to inflammatory diseases (including Behçet disease, relapsing polychondritis, IgG4-related disease, Cogan syndrome, ankylosing spondylitis). After a median follow-up of 52 months, vascular complications were observed in 32.3%, revascularizations in 30% of patients, and death in 7.6%. The 5-year cumulative incidence of vascular complications was 58% (95% CI 41-71), 20% (95% CI 13-29), and 19% (95% CI 11-28) in CIA, GCA, and TA, respectively. In multivariate analysis, male sex (HR 2.10, 95% CI 1.45-3.05, P < 0.0001) and CIA (HR 1.76, 95% CI 1.11-2.81, P = 0.02) were independently associated with vascular complications. CONCLUSION Noninfectious aortitis accounts for significant morbidity and mortality. CIA seems to carry the highest rate of vascular complications.
Collapse
Affiliation(s)
- Yasmina Ferfar
- Y. Ferfar, MD, M. Vautier, MD, C. Comarmond, MD, PhD, A.C. Desbois, MD, PhD, F. Domont, MD, P. Cacoub, MD, D. Saadoun, MD, PhD, Sorbonne Universités, Department of Internal Medicine and Clinical Immunology, Centre de Référence des Maladies Auto-Immunes Systémiques Rares, Centre de Référence des Maladies Auto-Inflammatoires et de l'Amylose inflammatoire, Paris; S. Morinet, MD, M. Resche-Rigon, MD, PhD, L. Biard, MD, PhD, AP-HP Department of Biostatistics and Medical Information, Hôpital Saint-Louis; ECSTRRA Team, CRESS UMR 1153, INSERM, University of Paris, Paris; 3O. Espitia, MD, PhD, C. Agard, MD, PhD, Department of Internal Medicine, CHU Nantes, Nantes, France. S. Morinet and O. Espitia contributed equally to this work. DS has received consulting and lecturing fees from Medimmune, AbbVie, Bristol Myers Squibb, Amgen, Celgene, Sanofi-Genzyme, Roche-Chugai, Servier, Gilead, AstraZeneca, and GlaxoSmithKline. PC has received consulting and lecturing fees from AbbVie, AstraZeneca, Bristol Myers Squibb, Gilead, GlaxoSmithKline, Janssen, MSD, Roche, Servier, and Vifor. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D. Saadoun, Département de Médecine Interne et d'Immunologie Clinique, Hôpital Pitié-Salpêtrière, 83 boulevard de l'hôpital, 75013 Paris, France. . Accepted for publication April 12, 2021
| | - Sarah Morinet
- Y. Ferfar, MD, M. Vautier, MD, C. Comarmond, MD, PhD, A.C. Desbois, MD, PhD, F. Domont, MD, P. Cacoub, MD, D. Saadoun, MD, PhD, Sorbonne Universités, Department of Internal Medicine and Clinical Immunology, Centre de Référence des Maladies Auto-Immunes Systémiques Rares, Centre de Référence des Maladies Auto-Inflammatoires et de l'Amylose inflammatoire, Paris; S. Morinet, MD, M. Resche-Rigon, MD, PhD, L. Biard, MD, PhD, AP-HP Department of Biostatistics and Medical Information, Hôpital Saint-Louis; ECSTRRA Team, CRESS UMR 1153, INSERM, University of Paris, Paris; 3O. Espitia, MD, PhD, C. Agard, MD, PhD, Department of Internal Medicine, CHU Nantes, Nantes, France. S. Morinet and O. Espitia contributed equally to this work. DS has received consulting and lecturing fees from Medimmune, AbbVie, Bristol Myers Squibb, Amgen, Celgene, Sanofi-Genzyme, Roche-Chugai, Servier, Gilead, AstraZeneca, and GlaxoSmithKline. PC has received consulting and lecturing fees from AbbVie, AstraZeneca, Bristol Myers Squibb, Gilead, GlaxoSmithKline, Janssen, MSD, Roche, Servier, and Vifor. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D. Saadoun, Département de Médecine Interne et d'Immunologie Clinique, Hôpital Pitié-Salpêtrière, 83 boulevard de l'hôpital, 75013 Paris, France. . Accepted for publication April 12, 2021
| | - Olivier Espitia
- Y. Ferfar, MD, M. Vautier, MD, C. Comarmond, MD, PhD, A.C. Desbois, MD, PhD, F. Domont, MD, P. Cacoub, MD, D. Saadoun, MD, PhD, Sorbonne Universités, Department of Internal Medicine and Clinical Immunology, Centre de Référence des Maladies Auto-Immunes Systémiques Rares, Centre de Référence des Maladies Auto-Inflammatoires et de l'Amylose inflammatoire, Paris; S. Morinet, MD, M. Resche-Rigon, MD, PhD, L. Biard, MD, PhD, AP-HP Department of Biostatistics and Medical Information, Hôpital Saint-Louis; ECSTRRA Team, CRESS UMR 1153, INSERM, University of Paris, Paris; 3O. Espitia, MD, PhD, C. Agard, MD, PhD, Department of Internal Medicine, CHU Nantes, Nantes, France. S. Morinet and O. Espitia contributed equally to this work. DS has received consulting and lecturing fees from Medimmune, AbbVie, Bristol Myers Squibb, Amgen, Celgene, Sanofi-Genzyme, Roche-Chugai, Servier, Gilead, AstraZeneca, and GlaxoSmithKline. PC has received consulting and lecturing fees from AbbVie, AstraZeneca, Bristol Myers Squibb, Gilead, GlaxoSmithKline, Janssen, MSD, Roche, Servier, and Vifor. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D. Saadoun, Département de Médecine Interne et d'Immunologie Clinique, Hôpital Pitié-Salpêtrière, 83 boulevard de l'hôpital, 75013 Paris, France. . Accepted for publication April 12, 2021
| | - Christian Agard
- Y. Ferfar, MD, M. Vautier, MD, C. Comarmond, MD, PhD, A.C. Desbois, MD, PhD, F. Domont, MD, P. Cacoub, MD, D. Saadoun, MD, PhD, Sorbonne Universités, Department of Internal Medicine and Clinical Immunology, Centre de Référence des Maladies Auto-Immunes Systémiques Rares, Centre de Référence des Maladies Auto-Inflammatoires et de l'Amylose inflammatoire, Paris; S. Morinet, MD, M. Resche-Rigon, MD, PhD, L. Biard, MD, PhD, AP-HP Department of Biostatistics and Medical Information, Hôpital Saint-Louis; ECSTRRA Team, CRESS UMR 1153, INSERM, University of Paris, Paris; 3O. Espitia, MD, PhD, C. Agard, MD, PhD, Department of Internal Medicine, CHU Nantes, Nantes, France. S. Morinet and O. Espitia contributed equally to this work. DS has received consulting and lecturing fees from Medimmune, AbbVie, Bristol Myers Squibb, Amgen, Celgene, Sanofi-Genzyme, Roche-Chugai, Servier, Gilead, AstraZeneca, and GlaxoSmithKline. PC has received consulting and lecturing fees from AbbVie, AstraZeneca, Bristol Myers Squibb, Gilead, GlaxoSmithKline, Janssen, MSD, Roche, Servier, and Vifor. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D. Saadoun, Département de Médecine Interne et d'Immunologie Clinique, Hôpital Pitié-Salpêtrière, 83 boulevard de l'hôpital, 75013 Paris, France. . Accepted for publication April 12, 2021
| | - Mathieu Vautier
- Y. Ferfar, MD, M. Vautier, MD, C. Comarmond, MD, PhD, A.C. Desbois, MD, PhD, F. Domont, MD, P. Cacoub, MD, D. Saadoun, MD, PhD, Sorbonne Universités, Department of Internal Medicine and Clinical Immunology, Centre de Référence des Maladies Auto-Immunes Systémiques Rares, Centre de Référence des Maladies Auto-Inflammatoires et de l'Amylose inflammatoire, Paris; S. Morinet, MD, M. Resche-Rigon, MD, PhD, L. Biard, MD, PhD, AP-HP Department of Biostatistics and Medical Information, Hôpital Saint-Louis; ECSTRRA Team, CRESS UMR 1153, INSERM, University of Paris, Paris; 3O. Espitia, MD, PhD, C. Agard, MD, PhD, Department of Internal Medicine, CHU Nantes, Nantes, France. S. Morinet and O. Espitia contributed equally to this work. DS has received consulting and lecturing fees from Medimmune, AbbVie, Bristol Myers Squibb, Amgen, Celgene, Sanofi-Genzyme, Roche-Chugai, Servier, Gilead, AstraZeneca, and GlaxoSmithKline. PC has received consulting and lecturing fees from AbbVie, AstraZeneca, Bristol Myers Squibb, Gilead, GlaxoSmithKline, Janssen, MSD, Roche, Servier, and Vifor. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D. Saadoun, Département de Médecine Interne et d'Immunologie Clinique, Hôpital Pitié-Salpêtrière, 83 boulevard de l'hôpital, 75013 Paris, France. . Accepted for publication April 12, 2021
| | - Cloé Comarmond
- Y. Ferfar, MD, M. Vautier, MD, C. Comarmond, MD, PhD, A.C. Desbois, MD, PhD, F. Domont, MD, P. Cacoub, MD, D. Saadoun, MD, PhD, Sorbonne Universités, Department of Internal Medicine and Clinical Immunology, Centre de Référence des Maladies Auto-Immunes Systémiques Rares, Centre de Référence des Maladies Auto-Inflammatoires et de l'Amylose inflammatoire, Paris; S. Morinet, MD, M. Resche-Rigon, MD, PhD, L. Biard, MD, PhD, AP-HP Department of Biostatistics and Medical Information, Hôpital Saint-Louis; ECSTRRA Team, CRESS UMR 1153, INSERM, University of Paris, Paris; 3O. Espitia, MD, PhD, C. Agard, MD, PhD, Department of Internal Medicine, CHU Nantes, Nantes, France. S. Morinet and O. Espitia contributed equally to this work. DS has received consulting and lecturing fees from Medimmune, AbbVie, Bristol Myers Squibb, Amgen, Celgene, Sanofi-Genzyme, Roche-Chugai, Servier, Gilead, AstraZeneca, and GlaxoSmithKline. PC has received consulting and lecturing fees from AbbVie, AstraZeneca, Bristol Myers Squibb, Gilead, GlaxoSmithKline, Janssen, MSD, Roche, Servier, and Vifor. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D. Saadoun, Département de Médecine Interne et d'Immunologie Clinique, Hôpital Pitié-Salpêtrière, 83 boulevard de l'hôpital, 75013 Paris, France. . Accepted for publication April 12, 2021
| | - Anne Claire Desbois
- Y. Ferfar, MD, M. Vautier, MD, C. Comarmond, MD, PhD, A.C. Desbois, MD, PhD, F. Domont, MD, P. Cacoub, MD, D. Saadoun, MD, PhD, Sorbonne Universités, Department of Internal Medicine and Clinical Immunology, Centre de Référence des Maladies Auto-Immunes Systémiques Rares, Centre de Référence des Maladies Auto-Inflammatoires et de l'Amylose inflammatoire, Paris; S. Morinet, MD, M. Resche-Rigon, MD, PhD, L. Biard, MD, PhD, AP-HP Department of Biostatistics and Medical Information, Hôpital Saint-Louis; ECSTRRA Team, CRESS UMR 1153, INSERM, University of Paris, Paris; 3O. Espitia, MD, PhD, C. Agard, MD, PhD, Department of Internal Medicine, CHU Nantes, Nantes, France. S. Morinet and O. Espitia contributed equally to this work. DS has received consulting and lecturing fees from Medimmune, AbbVie, Bristol Myers Squibb, Amgen, Celgene, Sanofi-Genzyme, Roche-Chugai, Servier, Gilead, AstraZeneca, and GlaxoSmithKline. PC has received consulting and lecturing fees from AbbVie, AstraZeneca, Bristol Myers Squibb, Gilead, GlaxoSmithKline, Janssen, MSD, Roche, Servier, and Vifor. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D. Saadoun, Département de Médecine Interne et d'Immunologie Clinique, Hôpital Pitié-Salpêtrière, 83 boulevard de l'hôpital, 75013 Paris, France. . Accepted for publication April 12, 2021
| | - Fanny Domont
- Y. Ferfar, MD, M. Vautier, MD, C. Comarmond, MD, PhD, A.C. Desbois, MD, PhD, F. Domont, MD, P. Cacoub, MD, D. Saadoun, MD, PhD, Sorbonne Universités, Department of Internal Medicine and Clinical Immunology, Centre de Référence des Maladies Auto-Immunes Systémiques Rares, Centre de Référence des Maladies Auto-Inflammatoires et de l'Amylose inflammatoire, Paris; S. Morinet, MD, M. Resche-Rigon, MD, PhD, L. Biard, MD, PhD, AP-HP Department of Biostatistics and Medical Information, Hôpital Saint-Louis; ECSTRRA Team, CRESS UMR 1153, INSERM, University of Paris, Paris; 3O. Espitia, MD, PhD, C. Agard, MD, PhD, Department of Internal Medicine, CHU Nantes, Nantes, France. S. Morinet and O. Espitia contributed equally to this work. DS has received consulting and lecturing fees from Medimmune, AbbVie, Bristol Myers Squibb, Amgen, Celgene, Sanofi-Genzyme, Roche-Chugai, Servier, Gilead, AstraZeneca, and GlaxoSmithKline. PC has received consulting and lecturing fees from AbbVie, AstraZeneca, Bristol Myers Squibb, Gilead, GlaxoSmithKline, Janssen, MSD, Roche, Servier, and Vifor. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D. Saadoun, Département de Médecine Interne et d'Immunologie Clinique, Hôpital Pitié-Salpêtrière, 83 boulevard de l'hôpital, 75013 Paris, France. . Accepted for publication April 12, 2021
| | - Matthieu Resche-Rigon
- Y. Ferfar, MD, M. Vautier, MD, C. Comarmond, MD, PhD, A.C. Desbois, MD, PhD, F. Domont, MD, P. Cacoub, MD, D. Saadoun, MD, PhD, Sorbonne Universités, Department of Internal Medicine and Clinical Immunology, Centre de Référence des Maladies Auto-Immunes Systémiques Rares, Centre de Référence des Maladies Auto-Inflammatoires et de l'Amylose inflammatoire, Paris; S. Morinet, MD, M. Resche-Rigon, MD, PhD, L. Biard, MD, PhD, AP-HP Department of Biostatistics and Medical Information, Hôpital Saint-Louis; ECSTRRA Team, CRESS UMR 1153, INSERM, University of Paris, Paris; 3O. Espitia, MD, PhD, C. Agard, MD, PhD, Department of Internal Medicine, CHU Nantes, Nantes, France. S. Morinet and O. Espitia contributed equally to this work. DS has received consulting and lecturing fees from Medimmune, AbbVie, Bristol Myers Squibb, Amgen, Celgene, Sanofi-Genzyme, Roche-Chugai, Servier, Gilead, AstraZeneca, and GlaxoSmithKline. PC has received consulting and lecturing fees from AbbVie, AstraZeneca, Bristol Myers Squibb, Gilead, GlaxoSmithKline, Janssen, MSD, Roche, Servier, and Vifor. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D. Saadoun, Département de Médecine Interne et d'Immunologie Clinique, Hôpital Pitié-Salpêtrière, 83 boulevard de l'hôpital, 75013 Paris, France. . Accepted for publication April 12, 2021
| | - Patrice Cacoub
- Y. Ferfar, MD, M. Vautier, MD, C. Comarmond, MD, PhD, A.C. Desbois, MD, PhD, F. Domont, MD, P. Cacoub, MD, D. Saadoun, MD, PhD, Sorbonne Universités, Department of Internal Medicine and Clinical Immunology, Centre de Référence des Maladies Auto-Immunes Systémiques Rares, Centre de Référence des Maladies Auto-Inflammatoires et de l'Amylose inflammatoire, Paris; S. Morinet, MD, M. Resche-Rigon, MD, PhD, L. Biard, MD, PhD, AP-HP Department of Biostatistics and Medical Information, Hôpital Saint-Louis; ECSTRRA Team, CRESS UMR 1153, INSERM, University of Paris, Paris; 3O. Espitia, MD, PhD, C. Agard, MD, PhD, Department of Internal Medicine, CHU Nantes, Nantes, France. S. Morinet and O. Espitia contributed equally to this work. DS has received consulting and lecturing fees from Medimmune, AbbVie, Bristol Myers Squibb, Amgen, Celgene, Sanofi-Genzyme, Roche-Chugai, Servier, Gilead, AstraZeneca, and GlaxoSmithKline. PC has received consulting and lecturing fees from AbbVie, AstraZeneca, Bristol Myers Squibb, Gilead, GlaxoSmithKline, Janssen, MSD, Roche, Servier, and Vifor. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D. Saadoun, Département de Médecine Interne et d'Immunologie Clinique, Hôpital Pitié-Salpêtrière, 83 boulevard de l'hôpital, 75013 Paris, France. . Accepted for publication April 12, 2021
| | - Lucie Biard
- Y. Ferfar, MD, M. Vautier, MD, C. Comarmond, MD, PhD, A.C. Desbois, MD, PhD, F. Domont, MD, P. Cacoub, MD, D. Saadoun, MD, PhD, Sorbonne Universités, Department of Internal Medicine and Clinical Immunology, Centre de Référence des Maladies Auto-Immunes Systémiques Rares, Centre de Référence des Maladies Auto-Inflammatoires et de l'Amylose inflammatoire, Paris; S. Morinet, MD, M. Resche-Rigon, MD, PhD, L. Biard, MD, PhD, AP-HP Department of Biostatistics and Medical Information, Hôpital Saint-Louis; ECSTRRA Team, CRESS UMR 1153, INSERM, University of Paris, Paris; 3O. Espitia, MD, PhD, C. Agard, MD, PhD, Department of Internal Medicine, CHU Nantes, Nantes, France. S. Morinet and O. Espitia contributed equally to this work. DS has received consulting and lecturing fees from Medimmune, AbbVie, Bristol Myers Squibb, Amgen, Celgene, Sanofi-Genzyme, Roche-Chugai, Servier, Gilead, AstraZeneca, and GlaxoSmithKline. PC has received consulting and lecturing fees from AbbVie, AstraZeneca, Bristol Myers Squibb, Gilead, GlaxoSmithKline, Janssen, MSD, Roche, Servier, and Vifor. The remaining authors declare no conflicts of interest relevant to this article. Address correspondence to Dr. D. Saadoun, Département de Médecine Interne et d'Immunologie Clinique, Hôpital Pitié-Salpêtrière, 83 boulevard de l'hôpital, 75013 Paris, France. . Accepted for publication April 12, 2021
| | | | | |
Collapse
|